Although immunotherapy targeting programmed cell death protein‐1/programmed cell death‐ligand 1 (PD‐1/PD‐L1) has emerged as the second‐line treatment for advanced ESCC,5, 6 the overall response rate is approximately 20%.7 The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.